Wall Street analysts expect that Intersect ENT Inc (NASDAQ:XENT) will report sales of $30.85 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Intersect ENT’s earnings, with estimates ranging from $29.98 million to $31.22 million. Intersect ENT posted sales of $32.78 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 5.9%. The business is scheduled to announce its next quarterly earnings results on Monday, February 24th.
According to Zacks, analysts expect that Intersect ENT will report full-year sales of $108.62 million for the current fiscal year, with estimates ranging from $108.10 million to $109.32 million. For the next fiscal year, analysts expect that the company will report sales of $122.34 million, with estimates ranging from $117.23 million to $133.05 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Intersect ENT.
Intersect ENT (NASDAQ:XENT) last announced its earnings results on Friday, November 1st. The medical equipment provider reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.01). Intersect ENT had a negative return on equity of 34.19% and a negative net margin of 36.37%. The business had revenue of $24.06 million for the quarter, compared to analysts’ expectations of $24.08 million. During the same quarter last year, the firm earned ($0.25) earnings per share. The firm’s quarterly revenue was down 2.5% compared to the same quarter last year.
In related news, insider Robert H. Binney, Jr. sold 25,584 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $21.54, for a total value of $551,079.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.90% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in XENT. Quadrant Capital Group LLC acquired a new stake in Intersect ENT during the third quarter worth about $36,000. Quantamental Technologies LLC raised its stake in Intersect ENT by 133.6% in the second quarter. Quantamental Technologies LLC now owns 4,555 shares of the medical equipment provider’s stock valued at $104,000 after buying an additional 2,605 shares in the last quarter. Nisa Investment Advisors LLC acquired a new stake in Intersect ENT in the third quarter valued at $208,000. Cubist Systematic Strategies LLC raised its stake in Intersect ENT by 106.1% in the second quarter. Cubist Systematic Strategies LLC now owns 18,013 shares of the medical equipment provider’s stock valued at $410,000 after buying an additional 9,275 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new stake in Intersect ENT in the second quarter valued at $539,000. Institutional investors and hedge funds own 97.20% of the company’s stock.
NASDAQ:XENT traded up $0.04 on Tuesday, reaching $21.52. The stock had a trading volume of 277,780 shares, compared to its average volume of 372,126. The stock has a market cap of $678.20 million, a P/E ratio of -28.32 and a beta of 0.78. The company has a 50-day moving average of $20.74 and a 200 day moving average of $19.73. Intersect ENT has a 12-month low of $14.61 and a 12-month high of $35.87.
About Intersect ENT
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Recommended Story: What Does a Sell-Side Analyst Rating Mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.